Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL-Reference-Cited by-同舟云学术

Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL

Published:2014-10-08 Issue:11 Volume:31 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

el Aziz Lamiss Mohamed Abd

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-014-0244-9.pdf

Reference28 articles.

1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1002–6.

2. Salles G, Shipp MA, Coiffier B. Chemotherapy of non Hodgkin aggressive lymphoma. Semin Hematol. 1994;31:46.

3. Sud R, Friedberg JW. Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab. Haematologica. 2008;93:1776–80.

4. Armitage JO. Staging systems for aggressive non-Hodgkin’s lymphoma. Ann Oncol. 1992;3:675–6.

5. Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma—results of a comprehensive meta-analysis. Cancer Treat Rev. 2007;33(4):338–46.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pro-apoptosis Effect of Survivin T34A Mutant on Cancer Cells in Vitro and Vivo;J INT TRANSL MED;2014